ACB Stock Chart & Stats
$3.66
-$0.24(-5.15%)
At close: 4:00 PM EST
$3.66
-$0.24(-5.15%)
Day’s Range― - ―
52-Week Range$2.56 - $6.67
Previous Close$4.5
Volume634.82K
Average Volume (3M)1.20M
Market Cap
$162.84M
Enterprise Value$122.39
Total Cash (Recent Filing)$164.69M
Total Debt (Recent Filing)$23.86M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.14
Shares Outstanding61,942,146
10 Day Avg. Volume1,198,199
30 Day Avg. Volume1,204,582
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.37Price Target Upside19.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.2
Revenue Forecast (FY)$203.48M
Bulls Say, Bears Say
Bulls Say
International DiversificationA majority-international revenue mix and FY2026 top-line growth reduce single-market regulatory and reimbursement concentration. Durable international footholds in regulated medical markets create more stable demand and higher-margin channels that can sustain revenue through Canadian policy cycles.
Industry-leading Margins & EBITDA GrowthStrong adjusted gross margins and meaningful adjusted EBITDA expansion demonstrate structural cost control and favorable product mix in medical markets. High margins provide operating leverage, building a cushion to absorb policy shocks while funding international expansion and margin-accretive investments.
Strong Liquidity & Balance Sheet FlexibilityRobust cash on hand, negligible debt and an active shelf/ATM provide multi-quarter financing optionality for capex, M&A and working capital. This balance-sheet strength materially lowers near-term solvency risk and enables execution of capacity expansion without immediate reliance on operating cash flow.
Bears Say
Canadian Reimbursed-Rate CutA ~30% cut in reimbursed pricing is a structural, regulatory-driven revenue and margin headwind for Canadian medical products. Even with international growth, sustained reimbursement pressure materially reduces unit economics in a core market and forces margin recovery via mix shift or cost cuts.
FY2027 Reset Guidance — Lower Revenue And EBITDAManagement's explicit FY2027 reset guidance signals a multi-quarter structural setback: lower revenue and more variable EBITDA limit near-term earnings predictability and capital generation, complicating reinvestment timing and making operating performance dependent on successful international scale-up.
Inconsistent Cash Generation & Recurring LossesReturn to negative operating cash flow and persistent free-cash-flow deficits indicate fragile internal cash generation. Over several quarters this raises reliance on financing, constrains organic investment, and amplifies execution risk if international margin improvements or M&A synergies take longer than planned.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was $2.56 and its highest was $6.67 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is $162.84M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Aurora Cannabis (US)’s earnings last quarter?
Aurora Cannabis (US) released its earnings results on Jun 11, 2026. The company reported -$0.341 earnings per share for the quarter, missing the consensus estimate of -$0.041 by -$0.3.
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.12.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 61,942,146 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Aurora Cannabis (US) reported an EPS of -$0.341 in its last earnings report, missing expectations of -$0.041. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.37 (19.47% Upside)
$4.37 (19.47% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $47.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 27.3%
Last 30 Days ▲ 27.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.30%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Stock 12 Month Forecast
Average Price Target
$4.37
▲(19.47% Upside)
Technical Analysis
Ownership Overview
0.62% Insiders
0.08% Mutual Funds
0.03% Other Institutional Investors
95.70% Public Companies and
Individual Investors